Oncotarget is a prominent, peer-reviewed scientific research journal that focuses directly on cancer research. The journal is published by Impact Journals on a weekly basis, and was founded in 2010. The editors in chief include Mikhail Blagosklonny and Andrei V. Gudkov, both professors of the Roswell Park Cancer Institute in New York. The journal is broadening its reach beyond oncology to include: Gerotarget/Aging,Immunology/Microbiology, Neuropathology/Neuroscience, Endocrinology, Cardiology, Metabolism, Cell & Molecular Biology and Pharmacology.
MET amplification as a potential therapeutic target in gastric cancer, published in the Oncotarget journal by researchers Hisato Kawakami1, Isamu Okamoto1, Tokuzo Arao2, Wataru Okamoto1, Kazuko Matsumoto2, Hirokazu Taniguchi4, Kiyoko Kuwata1, Haruka Yamaguchi1, Kazuto Nishio2, Kazuhiko Nakagawa1, and Yasuhide Yamada, discusses the genetic modification of MET as a target in treatment of gastric cancer.
The MET gene is a mesenchymal-epithelial transition factor on ncbi.nlm.nih.gov. It is a gene, that when expressed, induces the production of the tyrosine-protein kinase receptor or hepatocyte growth factor receptor (HGFR). This gene codes for a precursor protein, that when processed and modified, becomes the building blocks of the mature tyrosine-protein kinase receptor that is present on the surface of cells. Mutations in this gene can cause papillary renal cell carcinoma, hepatocellular carcinoma, head and neck cancers on msubmit.net.
The researchers of Oncotarget in this study also analyzed the effects of MET tyrosine kinase inhibitors (MET-TKIs) with, and also, without MET amplification in the gastric cancer cells. The results show that the MET tyrosine kinase inhibitors induced the death of the gastric cancer cells by modifying and suppressing the expression expression of the MET gene. They also found that downstream MET signaling was weakened in gastric cancer cells that included the genetic amplification of MET.